The side effects ‘ EPS ’ , ‘ parkinsonism ’ , and ‘ tremor ’ were significantly more common in children and adolescents treated with aripiprazole than in those treated with placebo .
Conclusion Our meta- analysis provides evidence for a non-negligible incidence of acute EPS in children and adolescents treated with aripiprazole .
Background Both the US FDA and the European Medicines Agency ( EMA ) have approved aripiprazole for use in adolescents for specific indications .
Given the assumed favorable side-effect profile of aripiprazole , its use in children and adolescents has increased for both official and off-label indications ( anxiety disorders , eating disorders , personality disorders ) .
However , several cases of children and adolescents with new-onset  extrapyramidal symptoms ( EPS )  after commencing treatment with aripiprazole have been reported , and a more systematic appraisal of this possible risk is lacking .
Objective We conducted a systematic review and a meta- analysis to assess the evidence for acute EPS ( acute dystonia , akathisia , Parkinsonism ) associated with the use of aripiprazole in children and adolescents .
Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study.
OBJECTIVE The aim of this study was to conduct a prospect i ve safety and tolerability study of aripiprazole for the treatment of tics in children and adolescents with Tourette 's disorder ( TD ) . METHOD Eleven subjects ( 10 males ) with TD ( age 9 - 19 years , mean 13.36 , st and ard deviation [ SD ] 3.33 ) who did not respond or were unable to tolerate previous tic medication were treated with aripiprazole in an open-label , flexible-dosing study over 10 weeks . Tic severity was rated using the Yale Global Tic Severity Scale ( YGTSS ) and the Clinical Global Impressions Scale for tics ( CGI-Tics ) at baseline and at follow-up . RESULTS The mean ( + /-SD ) daily dose for aripiprazole was 4.5 + /- 3.0 mg . Mean ( + /-SD ) YGTSS Global Severity scores reduced from 61.82 + /- 13.49 at baseline to 33.73 + /- 15.18 at end point ; mean YGTSS total tic scores reduced from 28.18 + /- 7.74 at baseline to 16.73 + /- 7.54 at end point . Mean ( + /-SD ) CGI-Tic severity scores reduced from 4.45 + /- 0.52 ( moderate-marked ) at baseline to 3.18 + /- 0.60 ( mild ) at end point . On the CGI-Tic improvement scale , 10 ( 91 % ) subjects achieved 1 ( " very much improved " ) or 2 ( " much improved " ) at end point . Most common adverse effects included appetite increase and weight gain in 5 subjects , mild extrapyramidal effects in 7 subjects , and headaches and tiredness/fatigue in 7 subjects ; 1 subject experienced akathisia and muscle cramps . CONCLUSION Aripiprazole appears to be a safe and tolerable treatment in children and adolescents with TD that appears to reduce tics ; it should be further investigated as a treatment option in controlled trials
The side effects ‘ EPS ’ , ‘ parkinsonism ’ , and ‘ tremor ’ were significantly more common in children and adolescents treated with aripiprazole than in those treated with placebo .
Conclusion Our meta- analysis provides evidence for a non-negligible incidence of acute EPS in children and adolescents treated with aripiprazole .
Background Both the US FDA and the European Medicines Agency ( EMA ) have approved aripiprazole for use in adolescents for specific indications .
Given the assumed favorable side-effect profile of aripiprazole , its use in children and adolescents has increased for both official and off-label indications ( anxiety disorders , eating disorders , personality disorders ) .
However , several cases of children and adolescents with new-onset  extrapyramidal symptoms ( EPS )  after commencing treatment with aripiprazole have been reported , and a more systematic appraisal of this possible risk is lacking .
Objective We conducted a systematic review and a meta- analysis to assess the evidence for acute EPS ( acute dystonia , akathisia , Parkinsonism ) associated with the use of aripiprazole in children and adolescents .